natgillin/translations-raw huggingface dataset:
In CKD 5D patients, the primary evaluation of safety is based on the integrated analysis of data from 4 studies involving 557 CKD 5D patients treated with Fexeric for up to 1 year. 
Pri bolnikih s KLB 5D je primarna ocena varnosti temeljila na integrirani analizi podatkov iz 4 študij,
Table 1: Adverse reactions observed during clinical studies in which Fexeric was administered in CKD 5D patients on haemodialysis or peritoneal dialysis. 
Fexeric uporabljalo pri bolnikih s KLB 5D na hemodializi ali peritonealni dializi
Fexeric has been administered to over 400 patients ≥ 65 years of age in studies where the dose was titrated to achieve target serum phosphorus levels. 
Fexeric uporabili pri več kot 400 bolnikih ≥ 65 let.
Contact a doctor or poison control centre immediately if a child accidentally takes Fexeric. 
Če zdravilo Fexeric nenamerno zaužije otrok, se takoj obrnite na zdravnika ali center za zastrupitve.
There was no evidence of hepatic impairment or significant alteration of hepatic enzymes across the clinical studies with Fexeric, including the long-term studies. 
V kliničnih študijah z zdravilom Fexeric, vključno z dolgotrajnimi študijami, ni bilo dokazov o poslabšanem jetrnem delovanju ali pomembni spremembi vrednosti jetrnih encimov.
The Fexeric-bound phosphorus is then excreted from your body in faeces. 
Fosfor, ki se veže na zdravilo Fexeric, se potem iz telesa izloči z blatom.
Increases in ferritin and TSAT above safety thresholds are observed with Fexeric use. 
Pri uporabi zdravila Fexeric so opazili povečanje ravni feritina in TSAT nad varnostnimi mejnimi vrednostmi.
HDPE bottles with child-resistant closure with desiccant. 
Plastenke iz HDPE, ki imajo za otroke varno zaporko in vsebujejo sušilno sredstvo.
Results from subgroup analyses in the pivotal clinical study in dialysis patients show that the concomitant use of frequently co-prescribed medications in CKD patients (fluoroquinolones, tetracyclines, proton pump inhibitors, thyroid hormones, sertraline, Vitamin D, warfarin, acetylsalicylic acid) do not affect the efficacy of Fexeric with respect to its ability to lower serum 
zaviralcev protonske črpalke, ščitničnih hormonov, sertralina, vitamina D, varfarina, acetilsalicilne kisline) ne vplivajo na učinkovitost zdravila Fexeric glede njegove sposobnosti zniževanja ravni
Each film-coated tablet contains 1 g of ferric citrate coordination complex (equivalent to 210 mg of 
Ena filmsko obložena tableta vsebuje 1 g koordinacijskega kompleksa železovega citrata (kar je enako
General disorders and administration site 
Splošne težave in spremembe na mestu aplikacije
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE CONDITIONS OR RESTRICTIONS REGARDING SUPPLY OTHER CONDITIONS AND REQUIREMENTS OF THE CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL 
POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA
They are supplied in one pack size of 
Na voljo so v eni velikosti pakiranja po 200 tablet na plastenko.
If you take too much Fexeric, tell your doctor of pharmacist. 
Če ste vzeli večji odmerek zdravila Fexeric, kot bi smeli Če ste vzeli prevelik odmerek zdravila Fexeric, se posvetujte z zdravnikom ali farmacevtom.
abdominal pain/discomfort, nausea, vomiting, haemorrhoids, haematochezia, mucous stools, dyspepsia, flatulence, dry mouth 
hemoroidi, hematohezija, sluzasto blato, dispepsija, flatulenca, suha usta
Also contains sunset yellow FCF (E110), Allura Red AC (E129), see the package leaflet for futher 
Vsebuje tudi oranžno barvilo FCF (E110) in rdeče barvilo AC (E129); za dodatne informacije glejte
The most commonly reported adverse reactions in dialysis-dependent chronic kidney disease (CKD 5D) patients during treatment were discoloured faeces and diarrhoea occurring in 18% and 13% of patients, respectively. 
(KLB 5D), odvisno od dialize, sta bila obarvano blato in diareja, ki sta se pojavila pri 18 % oziroma
Name and address of the manufacturer(s) responsible for batch release 
A. IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ Ime in naslov izdelovalca, odgovornega za sproščanje serij
*Proportion of patients achieving serum phosphorus ≤ 5.5 mg/dl in CKD 5D patients; **Proportion of patients achieving serum phosphorus ≤ 4.0 mg/dl in CKD ND patients NAP: not applicable; SD: standard deviation 
* Delež bolnikov, ki so dosegli raven fosforja v serumu ≤ 5,5 mg/dl pri bolnikih s KLB 5D.
Table 2: Adverse reactions observed during clinical studies in which Fexeric was administered in CKD ND patients. 
Preglednica 1: Neželeni učinki, ki so jih opazili v kliničnih študijah, v katerih se je zdravilo
Fexeric contains sunset yellow FCF (E110) and Allura Red AC (E129) 
oranžno barvilo FCF (E110), rdeče barvilo AC (E129) in indigotin.
The active substance is ferric citrate coordination complex. 
Zdravilna učinkovina je koordinacijski kompleks železovega citrata.
Fexeric contains ferric citrate coordination complex as the active ingredient. 
Zdravilna učinkovina v zdravilu Fexeric je koordinacijski kompleks železovega citrata.
The most commonly reported adverse reactions in non-dialysis dependent CKD (CKD ND) patients during treatment were discoloured faeces, constipation and diarrhoea occurring in 27%, 13% and 11% of patients, respectively. 
(KLB ND), neodvisno od dialize, so bili obarvano blato (27 % bolnikov), zaprtost (13 %) in diareja
NAP 
Glejte
The other ingredients are pregelatinised starch, calcium stearate, hypromellose, titanium dioxide, triacetin, sunset yellow FCF (E110), allura red AC (E129), indigo carmine. 
Druge sestavine zdravila so predgeliran škrob, kalcijev stearat, hipromeloza, titanov oksid, triacetin,
Common side effects (may affect up to 1 in 10 people): abdominal distension or bloating nausea, vomiting 
Občasni neželeni učinki (pojavijo se lahko pri največ 1 od 100 bolnikov): spremembe izvidov preiskav železa v krvi,
Decreased appetite, hyperkalaemia, hypophosphataemia, increased appetite Dizziness, headache Palpitations, dyspnoea Malignant hypertension 
povečan tek omotica, glavobol palpitacije, dispneja maligna hipertenzija pljučni edem, sopenje diareja, obarvano blato bolečina/neugodje/napihnjenost v trebuhu, zaprtost,
System Organ Class by MedDRA 
Fexeric uporabljalo pri bolnikih s KLB ND Organski sistem po MedDRA
The target organ for primary toxicity of ferric citrate is the GI tract, with evidence of mucosal erosion and acute to sub-acute inflammation of the GI tract in dogs at elevated doses. 
Pri psih so ob povečanih odmerkih odkrili dokaze erozije sluznice in akutnega do subakutnega vnetja prebavil.
Consequently, ciprofloxacin should not be taken at the same time, but at least 2 hours before or after Fexeric. 
temveč vsaj 2 uri pred uporabo zdravila Fexeric ali 2 uri po njej.
This medicine contains ferric citrate coordination complex as the active substance. 
Zdravilna učinkovina v tem zdravilu je koordinacijski kompleks železovega citrata.
PHARMACEUTICAL PARTICULARS 
Pediatrična populacija
Skin and subcutaneous tissue disorders 
Po absorpciji tkiva
Uncommon side effects (may affect up to 1 in 100 people): changes in iron blood test results decreased or increased appetite indigestion, flatulence inflammation of stomach lining, ulcer of mucosal lining of the stomach or the first part of the bowel reflux of stomach juices in the oesophagus abnormal stools, irregularity in bowel movement shortness of breath, wheezing, abnormal breath sounds 
vnetje želodčne sluznice, ulkus (razjeda) želodčne sluznice ali prvega dela črevesa, refluks želodčnih sokov v požiralnik,
It is unknown whether Fexeric may pass through breast milk and affect your baby. 
Ni znano, ali lahko zdravilo Fexeric prehaja v
Magnetic resonance angiography 
Magnetno resonančna angiografija
Patients undergoing liver transplantation are at particular risk since the incidence of acute renal failure is high in this group. 
Bolniki, ki imajo presajena jetra, so še posebej izpostavljeni tveganju, saj je pojavnost akutne ledvične odpovedi v tej skupini velika.
This has not been seen following the small amounts given with injections into the joint. 
Tega niso opazili po dajanju majhnih količin kontrastnega sredstva z injekcijami v sklep.
Clinical consequences are unknown. 
Vpliv na klinično sliko ni znan.
This includes retention in the brain and in other tissues and organs. 
To vključuje zadrževanje v možganih in drugih tkivih in organih.
<Product name> is approved for use in children above two years of age. 
Kontrastno sredstvo <ime kontrastnega sredstva>je odobreno za uporabo pri otrocih, starejših od dveh let.
Target organ 
Tarčni organ
The existing product information shall be amended (insertion, replacement or deletion of the text as appropriate) to reflect the agreed wording as provided below. 
Spremembe, ki jih je treba vključiti v ustrezna poglavja informacij o zdravilu Obstoječe informacije o zdravilu je treba spremeniti (vstaviti, nadomestiti ali izbrisati besedila, kot je ustrezno) tako, da vsebujejo dogovorjeno besedilo, kot je navedeno spodaj.
Because of the lack of information on repeated administration, <Product name> injections should not be repeated unless the interval between injections is at least 7 days. 
Zaradi pomanjkanja podatkov o večkratni uporabi se odmerjanja kontrastnega sredstva <ime kontrastnega sredstva> ne sme ponavljati, razen če je presledek med injekcijama vsaj 7 dni.
Intravenous gadobenic acid (restriction of the indication - all references to other indications should be removed across the Product Information) 
Gadobenska kislina za intravensko uporabo (omejitve indikacij - vse sklice na druge indikacije je treba iz informacij za zdravilo izbrisati) Povzetek glavnih značilnosti zdravila
Annex III Amendments to relevant sections of the product information 
Priloga III Spremembe, ki jih je treba vključiti v ustrezna poglavja informacij o zdravilu
• Assessment of myocardial perfusion 
• ocena perfuzije miokarda
It helps your doctor to identify any abnormalities of your liver brain/spine, arteries or other parts of your body. 
Zdravniku pomaga ugotoviti nenormalnosti jeter možganov/hrbtenjače, arterij ali drugih delov vašega telesa.
The dose should be calculated based on the patient's body weight, and should not exceed the recommended dose per kilogram of body weight detailed in this section. 
Odmerek se izračuna na podlagi telesne mase bolnika in ne sme preseči priporočenega odmerka na kilogram telesne mase, kar je podrobneje opisano v tem poglavju.
Other body areas 
Drugi deli telesa
• Section 3 How to use <Product name> 
• Poglavje 3 Kako uporabljati kontrastno sredstvo <ime kontrastnega sredstva>
Brain and spine 
Možgani in hrbtenjača
• Assessment of cardiac masses or myocardial viability 
• ocena srca in myocardial viability
The lowest dose that provides sufficient enhancement for diagnostic purposes should be used. 
Uporabiti je treba najmanjši odmerek, ki zagotavlja zadostno povečanje kontrasta za diagnostične namene.
• Magnetic Resonance Angiography (MRA) for the assessment of stenoses, occlusions and collaterals in adults and children (above the age of 2 years). 
• Magnetnoresonančna angiografija (MRA) za oceno stenoze, zapore in kolateral pri odraslih in otrocih (starih več kot 2 leti).
• Specific applications in the heart include measurement of myocardial perfusion under pharmacological stress conditions and viability diagnostics ("delayed enhancement"). 
• Specifičnsa uporaba v srcu, vključno z meritvami perfuzije miokarda v farmakološko stresnih pogojih in ko je diagnostika potrebna v primeru življenske ogroženosti ("zakasnelo enhancement").
• Section 1 What <Product name> is and what it is used for 
• Poglavje 1 Kaj je kontrastno sredstvo <ime kontrastnega sredstva> in za kaj ga uporabljamo
between 40 and 120 minutes following the injection, depending on the individual imaging needs. 
od 40 do 120 minut po injiciranju, odvisno od slikanja, ki je potrebno pri posameznem bolniku
Studies have shown that small amounts of gadolinium can remain in the body, including the brain. 
Študije so pokazale, da lahko v telesu, tudi v možganih, ostanejo majhne količine gadolinija.
• MRI of the brain and spine in adults and children above the age of 2 years, where it improves the detection of lesions and provides diagnostic information additional to that obtained with unenhanced MRI (see section 5.1). 
• MRS možganov in hrbtenjače pri odraslih in otrocih (starih več kot 2 leti), kjer izboljža zaznavanje lezij in daje dodatne diagnostične podatke, poleg tistih, ki so pridobljeni z MRS z uporabo kontrastnega sredstva (glejte poglavje 5.1).
• MR imaging of the whole body in adults and children (above the age of 2 years) including head and neck region, thoracic space (including the heart and female breast), abdomen (pancreas and liver), abdomen (gastrointestinal tract), retroperitoneal space (kidney, adrenal glands), pelvis (prostate, bladder and uterus) and musculoskeletal system where it facilitates identification of abnormal structures or lesions and helps in differentiating normal from pathological tissues (see sections 4.2 and 
• MRS celega telesa pri odraslih in otrocih (starih več kot 2 leti), vključno glave in področje vratu, prsnega koša (vključno srce in dojk pri ženskah, trebuha (trebušna slinavka in jetra), trebuha (prebavil)retroperitonealnega prostora (ledvice, nadledvične žleze), medenice (prostata, mehur, in maternica) in mišično-kostega sistema, kjer pospešuje prepoznavanje nenormalnih struktur ali lezij in pomaga pri razlikovanju normalih tkiv od patoloških (glejte poglavji (see sections 4.2 and 5.1).
The amount in millilitre you will be injected depends on how much you weigh in kilogram of body weight. 
Količina (v mililitrih), ki jo boste prejeli, je odvisna od vaše telesne mase (izražene v kilogramih).
If an automatic contrast detection pulse sequence is not used for bolus timing, then a test bolus injection ≤2 mL of the agent should be used to calculate the appropriate scan delay. 
Če se ne uporabi avtomatske kontrastne detekcije zaporedja impulzov za časovno uskladitev bolusa, potem se uporabi injiciranje testnega bolusa v količini ≤ 2 ml sredstva za izračun primerne zakasnitve prenosa slike.
If use of <Product name> cannot be avoided, the dose should not exceed 0.1 mmol/kg body weight when used for MR of the brain and spine, MR-angiography breast MRI or whole body MRI and should not exceed 0.05 mmol/kg body weight when used for MR of the liver, kidneys, urinary tract or adrenal glands. 
Če se uporabi kontrastnega sredstva <ime kontrastnega sredstva> ni možno izogniti, odmerek ne sme preseči 0,1 mmol/kg telesne mase, če se uporablja za MR možganov ali hrbtenice, MR-angiografijo, MRI prsnega koša ali MRI celega telesa, in ne sme preseči 0,05 mmol/kg telesne mase,če se uporablja za MR jeter, ledvic, sečil ali nadledvičnih žlez.
Brain and Spine up to 60 minutes after the administration. 
Možgani in hrbtenjača do 60 minut po injiciranju
Signal intensity increases and non-clinical data show that gadolinium is released from linear GdCAs. 
Povečana jakost signala in predkliničini podatki kažejo, da se gadolinij sprošča iz linearnih GdCA.
More than one dose should not be used during a scan except for MR cardiac perfusion imaging where two separate doses of 0.05 mmol/kg body weight can be administered in the course of a single examination. 
Med slikanjem se ne sme uporabiti več kot en odmerek, razen za MR slikanje perfuzije srca, ko sta lahko uporabljena dva odmerka po 0,05 mmol/kg telesne mase za eno preiskavo.
• part for healthcare professionals: Post-contrast imaging acquisition: 
• del navodila namenjen samo za zdravstvene delavce Pridobivanje slik po uporabi kontrastnega sredstva: Jetra Dinamično slikanje:
Prior to administration of <Product name>, it is recommended that all patients are screened for renal dysfunction by obtaining laboratory tests. 
Pred uporabo kontrastnega sredstva <ime kontrastnega sredstva> je priporočljivo pri vseh bolnikih preveriti delovanje ledvic z laboratorijskimi preiskavami.
Intravenous gadoteric acid, gadobutrol, gadoteridol Summary of product characteristics 
Gadoterna kislina, gadobutrol, gadoteridol za intravensko uporabo
Delayed imaging: between 40 and 120 minutes following the injection, depending on the individual imaging needs. 
takoj po dajanju bolusne injekcije slikanje z zakasnitvijo: od 40 do 120 minut po injiciranju, odvisno od slikanja, ki je potrebno pri posameznem bolniku
As there is a possibility that NSF may occur with <Product name>, it should therefore be avoided in patients with severe renal impairment and in patients in the perioperative liver transplantation period unless the diagnostic information is essential and not available with non-contrast enhanced MRI. 
Ker obstaja možnost pojava NSF zaradi kontrastnega sredstva <ime kontrastnega sredstva>, se je njegovi uporabi pri bolnikih s hudo okvarjenim delovanjem ledvic in bolnikih v perioperativnem obdobju presaditve jeter treba izogibati, razen če je diagnostična informacija ključna ter je ni možno pridobiti z magnetnoresonančnim slikanjem (MRS) brez uporabe kontrastnega sredstva.
The recommended dose of <active substance name (INN)> in adult patients and children is 0.05 mmol/kg body weight (0.1 mL/kg of the 0.5 M solution). 
Priporočeni odmerek <ime učinkovine (INN)> pri odraslih in otrocih je 0,05 mmol/kg telesne mase (0,1 ml/kg 0,5 M raztopine).
Studies have shown that after exposure to GdCAs given intravenously at significantly higher doses than intra-articular products gadolinium is retained in the body. 
Študije so pokazale, da se po intravenski uporabi GdCAs gadolinij zadržuje v telesu v pomembno večjih odmerkih kot po intraartikularni uporabi kontrastnega sredstva.
<Product name> is a special dye (or contrast agent) which contains the rare earth metal gadolinium and improves images of the liver brain/spine, arteries and other body areas during MRI scans. 
Kontrastno sredstvo <ime kontrastnega sredstva> je posebno barvilo (ali kontrastno sredstvo), ki vsebuje redko kovino gadolinij, ki izboljša sliko jeter, možganov/hrbtenjače, arterij in drugih delov telesa pri magnetnoresonančnem slikanju (MRS).
Two separate injections of 0.05 mmol/kg body weight (each corresponding to 0.1 mL/kg of the 0.5 M solution) during rest and stress imaging. 
Dve ločeni injekciji po 0,05 mmol/kg telesne mase (vsaka ustreza 0,1 ml/kg 0,5 M raztopine) med mirovanjem in stresnim slikanjem
There have been reports of nephrogenic systemic fibrosis (NSF) associated with use of some gadolinium-containing contrast agents in patients with acute or chronic severe renal impairment (GFR< 30ml/min /1.73 m2). 
Pri bolnikih z akutno ali hudo kronično ledvično okvaro (GFR < 30 ml/min/1,73 m2) so poročali o nefrogeni sistemski fibrozi (NSF) v povezavi z uporabo nekaterih kontrastnih sredstev, ki vsebujejo gadolinij.
<Active substance name (INN)> is a linear GdCA. 
<Ime učinkovine (INN)> je linearno kontrastno sredstvo, ki vsebuje gadolinij (GdCA).
This medicine is for diagnostic use only. 
Kontrastno sredstvo je samo za diagnostične namene.
Head and neck region, thoracic space (including the heart and female breast), abdomen (gastrointestinal tract including pancreas), pelvis (prostate, bladder and uterus) and musculoskeletal system 
Področje glave in vratu, prsni koš (vključno srca in dojk pri ženskah, trebuha (prebavina in tudi trebušna slnavka), medenica (prostata, mehur, in maternica) in mišično-kosni sistem
Other body areas T1-weighted sequences to be acquired as either dynamic or static delayed imaging. 
Drugi deli telesa T1-obtežena sekvenca pridobljena z dinamičnim slikanjem ali statičnim slikanjem z zakasnitvijo.
T1-weighted sequences to be acquired as either dynamic or static delayed imaging. 
T1-obtežena sekvenca pridobljena z dinamičnim slikanjem ali statičnim slikanjem z zakasnitvijo.
<Product name> is a paramagnetic contrast agent for use in diagnostic magnetic resonance imaging (MRI) indicated for: of the liver in adults and children (above the age of 2 years) 
Kontrastno sredstvo <ime kontrastnega sredstva> je paramagnetno kontrastno sredstvo, ki se uporablja za diagnostično magnetnoresonančno slikanje (MRS) ki je indicirano za jeter pri odraslih in otrocih (starih več kot 2 leti)
MRA immediately after the administration, with scan delay calculated on the basis of test bolus or automatic bolus detection technique. 
MRA takoj po injiciranju, z zakasnitvijo prenosa slike, ki se določi na osnovi testnega bolusa ali detekcije bolusa z avtomatsko tehniko.
Liver, kidneys, urinary tract , adrenal glands 
Jetra, ledvice, sečila, nadledvične žleze
With the linear GdCAs this can cause dose-dependent increases in T1-weighted signal intensity in the brain, particularly in the dentate nucleus, globus pallidus, and thalamus. 
Z linearnimi GdCA lahko to povzročijo od odmerka odvisno povečanje s T1 obteženo jakost signala v možganih, zlasti v dentatnem jedru, globusu pallidusu in talamusu.
<Product name> is injected into a vein, usually in your arm just before the MRI scan. 
Kontrastno sredstvo <ime kontrastnega sredstva>se vbrizga v žilo, običajno na roki, neposredno pred MRS.
Section 4.1 Therapeutic indications <Product name> is indicated for the detection of focal liver lesions and provides information on the character of lesions in T1-weighted magnetic resonance imaging (MRI). 
Kontrastno sredstvo <ime kontrastnega sredstva> je indicirano za zaznavanje žariščnih lezij v jetrih in daje podatke o značilnostih lezij pri z T1 obteženem magnetnoresonančnem slikanju (MRS).
immediately after the administration, with scan delay calculated on the basis of test bolus or automatic bolus detection technique. 
takoj po injiciranju, z zakasnitvijo prenosa slike, ki se določi na osnovi testnega bolusa ali detekcije bolusa z avtomatsko tehniko.
The possible diagnostic advantages of using <active substance name (INN)> in patients who will require repeated scans should be weighed against the potential for deposition of gadolinium in the brain and other tissues. 
Pri bolnikih, pri katerih je potrebno ponovno slikanje, je treba pretehtati možne diagnostične prednosti uporabe <ime učinkovine (INN)> glede na možno nalaganje gadolinija v možganih in drugih tkivih.
Studies have shown that after exposure to GdCAs gadolinium is retained in the body. 
Študije so pokazale, da se po izpostavljenosti GdCA gadolinij zadržuje v telesu.
Post-contrast imaging acquisition: Liver 
Pridobivanje slik po uporabi kontrastnega sredstva: Jetra dinamično slikanje:
This medicinal product is for diagnostic use by intravenous administration only. 
Kontrastno sredstvo je samo za intravensko uporabo za diagnostične namene.
After intravenous administration of <active substance name (INN)> gadolinium can be retained in the brain and in other tissues of the body (bones, liver, kidneys, skin) and can cause dose-dependent increases in T1-weighted signal intensity in the brain , particularly in the dentate nucleus, globus pallidus, and thalamus. 
Po intravenski uporabi <ime učinkovine (INN)> se lahko gadolinij zadržuje v možganih in drugih telesnih tkivih (kosti, jetra, ledvice, koža) in lahko povzroči od odmerka odvisno povečanje s T1 obteženo jakost signala v možganih, zlasti v dentatnem jedru, globusu pallidusu in talamusu.
After administration of <active substance name (INN)> gadolinium can be retained in the brain and in other tissues of the body (bones, liver, kidneys, skin) and can cause dose-dependent increases in T1weighted signal intensity in the brain, particularly in the dentate nucleus, globus pallidus, and thalamus. 
Po uporabi <ime učinkovine (INN)> se lahko gadolinij zadržuje v možganih in drugih telesnih tkivih (kosti, jetra, ledvice, koža) in lahko povzroči od odmerka odvisno povečanje s T1 obteženo jakost signala v možganih, zlasti v dentatnem jedru, globusu pallidusu in talamusu.
A T1-weighted, gradient-echo sequence with a time resolution of 2 minutes or less should be acquired before contrast injection and repeated several times over a period of 5 to 8 min after a rapid intravenous contrast bolus injection. 
Slikanje je nato, po dajanju hitre intravenske bolus injekcije, potrebno nekajkrat ponoviti v časovnem intervalu 5 do 8 minut.